TSVT News and Press, 2seventy bio Inc. From 05/17/23

bbT369, a dual-targeted (CD79a/CD20) and CBLB gene edited autologous CAR T for non-Hodgkin lymphoma, showed edit-driven enhanced T cell activity in multiple preclinical models RESET, a novel TCR coupled antigen receptor architecture, displayed markedly increased targeting sensitivity and ...

Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from KarMMa-3 study of health-related quality of life in patients who received Abecma will b...

2023-05-06 12:58:06 ET 2seventy bio, Inc. (TSVT) Q1 2023 Earnings Call Transcript May 3, 2023 4:30 PM Company Participants Jenn Snyder - SVP of Corporate Affairs Nick Leschly - President, CEO & Director Philip Gregory - Chief Scientific Officer Steven Ber...

2023-05-03 18:10:44 ET 2seventy bio press release ( NASDAQ: TSVT ): Q1 GAAP EPS of -$1.08. Revenue of $41.62M (+394.3% Y/Y). For further details see: 2seventy bio GAAP EPS of -$1.08, revenue of $41.62M

Late-breaking oral presentation will show early findings from Phase I PLAT-08 study of SC-DARIC33, an investigational, potentially first-in-class CD33-targeting CAR T in pediatric and young adults with relapsed/refractory acute myeloid leukemia (AML) Updates on the Company’...

2seventy bio plans to present data at virtual Research and Development deep dive on May 19, 2023 2seventy bio, Inc. (Nasdaq: TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a preclinical $15 million milestone as part of the joint research a...

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will announce its first quarter 2023 financial results on Wednesday, May 3, 2023. 2seventy bio will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Par...

2023-04-19 14:00:09 ET Geron Corporation ( NASDAQ: GERN ) and CTI BioPharma ( NASDAQ: CTIC ) were among notable gainers in the blood cancer space after an accidental data release from a Phase 3 trial for multiple myeloma therapy Carvykti developed by Legend Biotech ( LEG...

2023-04-19 07:48:49 ET Legend Biotech ( NASDAQ: LEGN ) added 18% , and Jonson & Jonson ( NYSE: JNJ ), its partner for Carvykti CAR-T cell therapy, gained 1% on Wednesday pre-market after a leaked report showed that the treatment sharply reduced the risk of relapse in...

U.S. FDA accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application and has assigned a target action date of December 16, 2023 European Medicines Agency has validated Bristol Myers Squibb’s Type II variation application for Abecma ...